Cardinal Health Inc (CAH) stock price, news and key stats

Price

Last trade as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$232.53

Open

$233.33

Day range

$232.25 – $234.72

Volume

44.7K

52-week range

$145.87 – $258.30

Market cap

$54.1B

Forward P/E

16.5

Dividend yield

88.00%

Beta

0.52

Avg. volume

2.0M

Analyst target

$270.94

Next earnings

Nov 5, 2026

About Cardinal Health Inc

Latest CAH news

• We're booking a 300% profit in an AI winner and buying more of a healthcare name
  CNBC · Aug 24, 2026

  Jim Cramer’s Charitable Trust is capitalizing on a significant profit from its investment in Broadcom, selling 165 shares at approximately $361.27, which translates to a remarkable 300% gain. This strategic move reflects the ongoing strength of the semiconductor sector, particularly as demand for AI technologies continues to surge. Broadcom's robust performance has been driven by its critical role in supplying chips for various applications, including artificial intelligence, which has positioned the company as a key player in the tech landscape. In conjunction with the sale, the Trust is reallocating funds by purchasing 50 shares of Cardinal Health at around $229.25. This decision indicates a shift towards the healthcare sector, which remains resilient amid economic uncertainties. Investing in Cardinal Health could be seen as a hedge against volatility in tech stocks, as the healthcare industry typically offers stability and consistent demand. As the market navigates the complexities of inflation and interest rates, diversifying into healthcare may provide a balanced approach to portfolio management.

• Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story
  Yahoo Finance · Aug 19, 2026

  Cardinal Health (CAH) reported a significant earnings beat for its second quarter, showcasing robust profit growth that surpassed analysts' expectations. However, the company’s revenue figures fell short of Wall Street forecasts, raising concerns about the sustainability of its earnings momentum. Management attributed the profit increase to strong demand across its Pharmaceutical segment, but the revenue miss suggests potential underlying challenges in the broader market environment. The discrepancy between earnings and revenue growth could have implications for investor sentiment and stock performance moving forward. While the earnings beat may initially bolster confidence in Cardinal Health's operational efficiency, the revenue shortfall could indicate issues such as pricing pressures or shifts in demand that may affect future performance. Analysts will be closely monitoring the company's guidance and market conditions as it prepares to report its results for the quarter ending June 2026, where expectations are for a year-over-year increase in earnings driven by higher revenues. The mixed signals from this earnings report may lead to increased volatility in Cardinal Health's stock as investors weigh the potential risks against the company's demonstrated profitability.

• Non-PVC IV Bags Market Outlook Signals Expansion To $3.79 Billion Through 2030
  Market Outlook · Aug 19, 2026

  The non-PVC IV bags market is projected to experience significant growth, reaching an estimated value of $3.79 billion by 2030. This expansion is driven by increasing demand for safer and more environmentally friendly alternatives to traditional PVC bags, particularly in healthcare settings where patient safety is paramount. The shift towards non-PVC materials is largely influenced by rising awareness of the potential health risks associated with phthalates and other harmful chemicals found in PVC. Market analysts attribute this growth to several factors, including the rising incidence of chronic diseases that require intravenous therapies, an aging population, and advancements in medical technology. Additionally, regulatory pressures and a growing emphasis on sustainability are prompting healthcare providers to adopt non-PVC solutions. As hospitals and clinics seek to enhance patient care while adhering to environmental standards, the demand for non-PVC IV bags is expected to accelerate. Investors and manufacturers in the healthcare sector should closely monitor this trend, as the transition to non-PVC products could reshape supply chains and influence pricing strategies. Companies that innovate in this space may find themselves at a competitive advantage, particularly as healthcare facilities increasingly prioritize safety and sustainability in their procurement processes.

• Medical Low Value Consumables Market Outlook Signals Expansion To $17.36 Billion Through 2030
  Market Outlook · Aug 17, 2026

  The global medical low value consumables market is projected to expand significantly, reaching approximately $17.37 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.7%. This growth is largely attributed to the rising prevalence of chronic diseases and an increasing demand for continuous medical interventions. As healthcare systems worldwide adapt to these trends, the market for low-cost consumable items is expected to play a crucial role in supporting ongoing patient care and treatment. Major players in the medical supplies sector, including Medtronic plc, Cardinal Health, and Becton, Dickinson and Company, are well-positioned to benefit from this growth trajectory. The broader medical supplies market is also on an upward trend, projected to grow from $198.17 billion in 2026 to $318.77 billion by 2031, reflecting a robust CAGR of 9.97%. This indicates a healthy demand for medical products, which is likely to drive innovation and investment in the sector. As the healthcare landscape evolves, particularly in Europe, there is a shift towards industrial maturity, moving away from the fragmented market of the early 2020s. This transition is expected to enhance operational efficiencies and improve the delivery of care, further bolstering the demand for low value consumables. With the convergence of artificial intelligence and value-based care models, the medical consumables market is set to experience transformative changes that will shape healthcare delivery in the coming years.

• JPMorgan Chase & Co. Issues Positive Forecast for Cardinal Health (NYSE:CAH) Stock Price
  Bank Research · Aug 13, 2026

  JPMorgan Chase & Co. has issued an optimistic forecast for Cardinal Health (NYSE: CAH), raising its price target from $215 to $260 while maintaining a neutral rating. This adjustment suggests a potential upside of approximately 12.1% from the current share price, which closed at $234.16. The positive outlook aligns with broader analyst sentiment, as 15 analysts currently rate the stock as a Buy and three as a Hold, resulting in a Moderate Buy consensus with an average price target of $265.60. The revised price target reflects confidence in Cardinal Health's operational performance and market position, despite the neutral rating from JPMorgan. Analysts' forecasts for the stock range from a low of $215 to a high of $280, indicating a robust potential for growth. The average price target represents an increase of $9.58 from the last closing price, suggesting that investors may find value in the stock as it navigates market conditions. As the healthcare sector continues to evolve, Cardinal Health's strategic initiatives and financial health will be closely monitored by investors looking for opportunities in this space.

• Cardinal Health forecasts FY27 EPS of $12.40-$12.60 and at least $1B in share repurchases as board adds $5B to buyback authority
  Seeking Alpha · Aug 11, 2026

  Cardinal Health has issued a robust forecast for fiscal year 2027, projecting earnings per share (EPS) between $12.40 and $12.60. This optimistic outlook comes on the heels of a strong fourth quarter, driven primarily by the company’s Pharmaceutical and Specialty Solutions segment. CEO Jason Hollar highlighted the performance of this division as a key contributor to the company's overall success, suggesting a solid foundation for future growth. In a strategic move to enhance shareholder value, Cardinal Health's board has approved an increase of $5 billion to its share repurchase authority, indicating a commitment to returning capital to investors. The company plans to allocate at least $1 billion towards these buybacks, which could bolster EPS by reducing the number of shares outstanding. This aggressive buyback strategy, combined with the positive earnings forecast, may enhance investor confidence and support the stock price in a volatile market environment. As Cardinal Health continues to navigate the complexities of the healthcare sector, these initiatives could position the company favorably among its peers.

• This Drug Stock Has Crushed the S&P 500 Over the Last Decade
  Yahoo Finance · Apr 18, 2026

  Thirteen medical technology stocks have outperformed the S&P 500 in each of the past five years—a rare feat reflecting disciplined execution, resilient end-market demand, and improving earnings visibility. Unlike cyclical or sentiment-driven rallies, this sustained outperformance stems from structural tailwinds including aging demographics, procedural volume growth, and innovation-led adoption of minimally invasive and transplant-enabling technologies. Companies such as TransMedics, KORU Medical Systems, and Cardinal Health exemplify this cohort, delivering consistent revenue growth, margin expansion, and regulatory or commercial milestones that de-risk forward guidance. The medtech sector’s resilience contrasts with broader market volatility driven by macro uncertainty, interest rate sensitivity, and valuation compression in rate-sensitive segments like tech and growth equities. Medtech’s relatively stable cash flows, recurring revenue models (e.g., device servicing, disposables), and lower correlation to credit cycles have supported premium valuations—and in many cases, justified multiple expansion on improving fundamentals. Notably, these outperformers are not uniformly large-cap; several are mid- or small-cap innovators with targeted clinical solutions, suggesting niche leadership and scalable commercial infrastructure matter more than scale alone. From a portfolio construction standpoint, this group highlights how sector-specific regime shifts—such as accelerating transplant infrastructure investment or home-based care adoption—can create durable alpha opportunities independent of broad equity beta. For investors, the implication is twofold: first, earnings quality and execution clarity remain critical differentiators in a higher-for-longer rate environment; second, exposure to medtech must be refined beyond broad ETFs to capture idiosyncratic catalysts like FDA approvals, hospital contracting wins, or international commercialization inflection points.

Earnings history

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen